DK1180518T3 - 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf - Google Patents

5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf

Info

Publication number
DK1180518T3
DK1180518T3 DK00917375T DK00917375T DK1180518T3 DK 1180518 T3 DK1180518 T3 DK 1180518T3 DK 00917375 T DK00917375 T DK 00917375T DK 00917375 T DK00917375 T DK 00917375T DK 1180518 T3 DK1180518 T3 DK 1180518T3
Authority
DK
Denmark
Prior art keywords
pyridyl
preparation
azole compounds
azole
compounds
Prior art date
Application number
DK00917375T
Other languages
English (en)
Inventor
Shigenori Ohkawa
Seiji Miwatashi
Naoyuki Kanzaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK1180518T3 publication Critical patent/DK1180518T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
DK00917375T 1999-04-23 2000-04-20 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf DK1180518T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11668699 1999-04-23
JP22465099 1999-08-06
PCT/JP2000/002575 WO2000064894A1 (en) 1999-04-23 2000-04-20 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof

Publications (1)

Publication Number Publication Date
DK1180518T3 true DK1180518T3 (da) 2007-05-21

Family

ID=26454974

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00917375T DK1180518T3 (da) 1999-04-23 2000-04-20 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf

Country Status (24)

Country Link
US (3) US7101899B1 (da)
EP (1) EP1180518B1 (da)
KR (2) KR100449215B1 (da)
CN (1) CN1156471C (da)
AU (1) AU765473B2 (da)
BR (1) BR0009952A (da)
CA (1) CA2370264A1 (da)
CZ (1) CZ300709B6 (da)
DE (1) DE60033028T2 (da)
DK (1) DK1180518T3 (da)
ES (1) ES2275500T3 (da)
HK (1) HK1044338B (da)
HU (1) HUP0203766A3 (da)
IL (1) IL146105A (da)
MX (1) MXPA01010675A (da)
MY (1) MY126736A (da)
NO (1) NO320588B1 (da)
NZ (1) NZ515215A (da)
PL (1) PL351148A1 (da)
PT (1) PT1180518E (da)
RU (1) RU2237062C2 (da)
SI (1) SI1180518T1 (da)
SK (1) SK286666B6 (da)
WO (1) WO2000064894A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL351148A1 (en) 1999-04-23 2003-03-24 Takeda Chemical Industries Ltd 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
AU7922900A (en) 1999-10-27 2001-05-08 Novartis Ag Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
EP1268474A2 (en) * 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
WO2002046186A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
EP1354603A1 (en) * 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
EP1364949A4 (en) * 2001-02-02 2005-11-23 Takeda Pharmaceutical JNK INHIBITOR
CA2446939C (en) * 2001-05-16 2005-08-02 Matthias Stein-Gerlach Pyridylpyrimidine derivatives as effective compounds against prion diseases
WO2002096879A1 (en) * 2001-05-31 2002-12-05 Sanofi-Synthelabo Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
EP1402900A1 (en) * 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
IL160874A0 (en) * 2001-10-22 2004-08-31 Tanabe Seiyaku Co 4-imidazolin-2-one derivatives
US7473695B2 (en) 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
US7064139B2 (en) * 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
AU2003246927A1 (en) * 2002-07-03 2004-01-23 Astex Technology Limited 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
EP1554269A1 (en) 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
BR0313755A (pt) * 2002-08-23 2005-06-21 Rigel Pharmaceuticals Inc Composto, métodos para inibir a replicação ou proliferação de um vìrion da hepatite c e para tratar ou prevenir uma infecção por hcv, e, composição
US7326790B2 (en) 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
WO2005049065A2 (en) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
JP4638355B2 (ja) * 2003-12-26 2011-02-23 協和発酵キリン株式会社 チアゾール誘導体
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
US7678810B2 (en) * 2004-03-05 2010-03-16 Taisho Pharmaceutical Co., Ltd Thiazole derivative
JP2007223903A (ja) * 2004-07-09 2007-09-06 Takeda Chem Ind Ltd 新規な固体分散体およびその製造方法
ATE542817T1 (de) 2004-11-10 2012-02-15 Ono Pharmaceutical Co Stickstoffhaltige heterocyclische verbindung und deren pharmazeutische verwendung
CA2606106A1 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
WO2006137658A1 (en) * 2005-06-20 2006-12-28 Dongbu Hitek Co., Ltd. New substituted 1,3-thiazole derivatives or pharmaceutically acceptable salts thereof having immunosuppression and inflammation inhibitory acitivity, intermediate compounds or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and pharmaceutical composition comprising the same
US7494519B2 (en) * 2005-07-28 2009-02-24 3M Innovative Properties Company Abrasive agglomerate polishing method
CA2617817C (en) 2005-08-02 2014-05-27 Kyowa Kirin Co., Ltd. Thiazole derivatives for treating or preventing sleep disorders
US20090005568A1 (en) * 2005-08-18 2009-01-01 Pharmacopeia Drug Discovery, Inc. Substituted 2-aminothiazoles for treating neurodegenerative diseases
KR20080068839A (ko) 2005-10-03 2008-07-24 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그 의약 용도
CA2627497C (en) 2005-10-28 2014-10-14 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
EP1985283A4 (en) * 2006-01-18 2011-08-03 Next21 Kk GELPENDING COMPOSITION FOR USE IN MEDICINE, APPARATUS FOR THE APPLICATION OF THE COMPOSITION, AND MEDICAMENT-RELATED TAX CARRIER
US20090192164A1 (en) * 2006-06-28 2009-07-30 Aska Pharmaceutical Co., Ltd. Treating agent of inflammatory bowel disease
CA2661195A1 (en) 2006-08-21 2008-02-28 Next21 K.K. Bone model, bone filler and process for producing bone filler
JP4588791B2 (ja) 2007-02-16 2010-12-01 あすか製薬株式会社 微粒子油性懸濁液を含む医薬組成物
EP2140883B1 (en) 2007-04-20 2012-10-31 Daido Chemical Corporation Novel base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
EP2540286A4 (en) 2010-02-26 2015-05-27 Nisshin Kasei Co Ltd HARTKAPSEL AND METHOD FOR THE PRODUCTION THEREOF
WO2014050910A1 (ja) 2012-09-26 2014-04-03 武田薬品工業株式会社 固体粒子の製造方法
CN103288817A (zh) * 2013-07-02 2013-09-11 天津理工大学 一种基于1,3,4-噻二唑和1,3,4-噁二唑的希夫碱衍生物及其制备方法和应用
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
KR101851972B1 (ko) 2015-10-21 2018-06-11 주식회사 제이아이바이오팜 청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향을 포함하는 한약 추출물이 함유된 탈모개선 및 탈모방지용 복합조성물 및 그 제조방법
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3238711B1 (en) 2016-04-26 2023-07-12 Mitsubishi Chemical Corporation Base for solid dispersion, production method for solid dispersion using same, and solid dispersion
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
CN108017584B (zh) * 2017-06-20 2021-03-23 南开大学 A3腺苷受体的小分子拮抗剂
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486009T2 (de) 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
JPH0570446A (ja) 1991-09-13 1993-03-23 Taisho Pharmaceut Co Ltd Ｎ−チアゾリルスルホンアミド誘導体
DE69637948D1 (de) * 1995-10-06 2009-07-23 Merck & Co Inc Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung
US5684439A (en) * 1995-10-10 1997-11-04 Motorola, Inc. Half wave ceramic filter with open circuit at both ends
MY128323A (en) * 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
ATE257703T1 (de) 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
PL351148A1 (en) * 1999-04-23 2003-03-24 Takeda Chemical Industries Ltd 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
EP1402900A1 (en) * 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions

Also Published As

Publication number Publication date
EP1180518A1 (en) 2002-02-20
EP1180518A4 (en) 2004-09-15
CZ300709B6 (cs) 2009-07-22
US7101899B1 (en) 2006-09-05
IL146105A (en) 2005-09-25
NO20015156L (no) 2001-12-18
PT1180518E (pt) 2007-02-28
EP1180518B1 (en) 2007-01-17
DE60033028D1 (de) 2007-03-08
NO320588B1 (no) 2005-12-27
WO2000064894A1 (en) 2000-11-02
AU3840100A (en) 2000-11-10
RU2237062C2 (ru) 2004-09-27
CN1156471C (zh) 2004-07-07
KR20020059453A (ko) 2002-07-12
CA2370264A1 (en) 2000-11-02
KR20010111314A (ko) 2001-12-17
US7276527B2 (en) 2007-10-02
AU765473B2 (en) 2003-09-18
CN1353710A (zh) 2002-06-12
SK14952001A3 (sk) 2002-04-04
CZ20013805A3 (cs) 2002-04-17
PL351148A1 (en) 2003-03-24
NZ515215A (en) 2003-07-25
DE60033028T2 (de) 2007-11-15
IL146105A0 (en) 2002-07-25
HK1044338A1 (en) 2002-10-18
BR0009952A (pt) 2002-03-26
US20060135566A1 (en) 2006-06-22
HUP0203766A3 (en) 2008-01-28
NO20015156D0 (no) 2001-10-22
SI1180518T1 (sl) 2007-06-30
HUP0203766A2 (hu) 2003-03-28
ES2275500T3 (es) 2007-06-16
MXPA01010675A (es) 2002-06-04
KR100558123B1 (ko) 2006-03-07
SK286666B6 (sk) 2009-03-05
MY126736A (en) 2006-10-31
HK1044338B (en) 2007-06-29
KR100449215B1 (ko) 2004-09-18
US20090048307A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
DK1163244T3 (da) Thienopyrimidinforbindelser, fremstilling og anvendelse heraf
NO20015156L (no) 5-pyridyl-1,3-azolforbindelser, deres fremstilling og anvendelse
DK1345910T3 (da) Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
NO20021449D0 (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
NO20024281D0 (no) Indolderivater, fremgangsmåte for fremstilling av de samme og anvendelse derav
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
DK1261697T3 (da) Kuldeaktiv beta-galactosidase, fremgangsmåde til fremstilling heraf og anvendelsen deraf
IS5982A (is) Aðferð til framleiðslu á 5-sýanóþalíði
NO20005411D0 (no) Antipicornavirusforbindelser, deres fremstilling og anvendelse
EE200100574A (et) Uued ühendid, nende valmistamise meetod ning kasutamine
NO20022834D0 (no) Zeolitt SSZ-50, fremgangsmåte for fremstilling og anvendelse av denne
DK1265482T3 (da) Vandige formulationer og fremgangsmåde til fremstilling af samme
NO20030800D0 (no) Aminoalkylbenzoyl-benzofuran- eller benzotiofenderivater, fremgangsmåte forderes fremstilling og preparater inneholdende de samme
DK1202996T3 (da) Titanforbindelser, fremstilling og anvendelse heraf
DK1003383T3 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
DK1627631T3 (da) Morfinsulfatmikrogranuler, fremgangsmåde til fremstilling deraf og præparat omfattende samme
NO20013735D0 (no) Fremgangsmåte til fremstilling av di-iso-butaner, di-iso- butener og di-n-butener fra feltbutaner
DK1098891T3 (da) Polycycliske thiazolidin-2-yliden-aminer, fremgangsmåde til fremstilling deraf og deres anvendelse som lægemidler
EE200100573A (et) Uued ühendid, nende valmistamise meetod ning kasutamine
NO20033120D0 (no) 2-arylimino-2,3-dihydrotiazolderivater, fremgangsmater for fremstilling derav og terapeutisk anvendelse derav
NO20021947D0 (no) Bio-b¶rende matrikser, fremgangsmåte for fremstilling og anvendelse derav
DK1053224T3 (da) Biphenylfulfonylcyanamider, fremgangsmåde til fremstilling deraf og anvendelse deraf som lægemiddel